Aratana Therapeutics Inc (fka PETX)

[terry hallinan]

Biotech Researcher,

So, PETX received $5.4-$2.2 or $3.2 million of actual product revenue from Galliprant in Q3 2017, so on March 14th, we will have another data point on Galli’s organic growth rate. It should at least double, I hope..................

Hope has even fled the White House again. I don't put much store by that purported virtue but I would be very disappointed by a decline in retail sales which are not directly related to inventory sales.

In our case we had a devil of a time getting any Galliprant tablets because we first needed a prescription from a vet who knew nothing at all about the drug for our 7-year-old mixed border collie and then we quickly found we couldn't buy the drug anywhere in our area.

Happens when you live in the sticks.

There was a break because of another snafu after the first month's supply was used and the dog quickly became a cripple again.

Long term questions remain to be answered in the - ahem - long term and that is even now of great interest to our vet with his "animal hospital."

Galliprant as a first-in-class piprant does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions.

It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation1

https://www.galliprantfordogs.com/vet

Longterm safety questions remain.

How many many painfully crippled dogs from osteoarthritis like ours in our area are romping in the snow like a young pup.

- None that anyone knows about.

Even our clinic is waiting on answers.

In humans a ramp-up period for new drugs is much faster than in America but still can take 2 or 3 years to go mainstream.

I would guess it would be much the same with animals.

JMO.

Best, Terry